Galsulfase Approved in Brazil for the Treatment of Mucopolysaccharidosis VI
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Galsulfase Approved in Brazil for the Treatment of Mucopolysaccharidosis VI

NEW YORK -- February 3, 2009 -- Brazil's National Health Surveillance Agency (ANVISA) has approved galsulfase (Naglazyme) for the treatment of patients with mucopolysaccharidosis VI.

The most common adverse events observed in clinical trials in patients treated with galsulfase were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhoea, ear pain, cough, and otitis media.

Severe reactions included angioneurotic oedema, hypotension, dyspnoea, bronchospasm, respiratory distress, apnoea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued for adverse events.

Nearly all patients developed antibodies as a result of treatment, but the level of the immune response did not correlate with the severity of adverse events. Because antihistamine use may increase the risk of apnoeic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay galsulfase infusion should be given when treating patients who present with an acute febrile or respiratory illness.

SOURCE: BioMarin Pharmaceutical Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities